Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

/PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672, "Ascletis") dedicated to the research and...

Related Keywords

Hangzhou ,Zhejiang ,China ,Italy ,United States ,Milan ,Lombardia ,Hong Kong ,Chinese ,Americans ,Jinzij Wu , ,Hong Kong Stock Exchange ,Ascletis Pharma Inc ,Prnewswire Gannex Pharma Co Ltd ,Gannex Pharma Co Ltd ,Ascletis Pharma ,European Association ,Liver Enzymes ,Lipids Biomarkers ,